title: Fluticasone furoate and vilanterol trifenatate combination therapy for the treatment of asthma.
abstract: Combination inhaled corticosteroids (ICS) and long acting β2-adrenergic agonists (LABA) are used in a stepwise fashion for patients whose asthma is not controlled by low dose ICS alone. Adherence is one of the main issues facing clinicians in the control of asthma symptoms with currently available combination inhalers requiring twice-daily (BD) inhalation. Fluticasone furoate (FF) and vilanterol trifenatate (VI) both have prolonged retention in the lung with effects on lung function over 24-hours and as such the combination has been proposed for once-daily (OD) dosing.
  
  
  
  The stepwise pharmacologic approach to asthma management is addressed, followed by a detailed assessment of the literature pertaining to the efficacy, tolerability and safety of FF/VI combination therapy for the treatment of asthma. Expert commentary: Doses of 100/25µg and 200/25µg inhaled OD, have similar improvements in lung function, asthma control as well as rates of side effects to one of the currently available BD ICS/LABA combinations, fluticasone propionate and salmeterol (FP/SAL) but have not been compared with other commonly used combinations. It is hoped that OD dosage of FF/VI can improve adherence and hence asthma control in these patients, however evidence to support this has yet to become available.
authors.affiliation: a Department of Respiratory Medicine , Prince of Wales Hospital , Randwick , Australia.
authors.forename: Emma L
authors.initials: EL
authors.lastname: Gray
authors.affiliation: a Department of Respiratory Medicine , Prince of Wales Hospital , Randwick , Australia.
authors.forename: Vicky
authors.initials: V
authors.lastname: Chang
authors.affiliation: a Department of Respiratory Medicine , Prince of Wales Hospital , Randwick , Australia.|b Inflammation and Infection Research Centre, School of Medical Sciences , University of New South Wales , Randwick , Australia.
authors.forename: Paul S
authors.initials: PS
authors.lastname: Thomas
mesh_terms: D000730:Androstadienes / Q000494:pharmacology* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001592:Benzyl Alcohols / Q000494:pharmacology* / Q000627:therapeutic use; D002722:Chlorobenzenes / Q000494:pharmacology* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans
chemical_list: D000730:Androstadienes; D001592:Benzyl Alcohols; D002722:Chlorobenzenes; C550468:vilanterol; C523187:fluticasone furoate
keywords: Asthma; combination ICS/LABA; fluticasone furoate; vilanterol trifenatate